RxDoctor Payments Data

Annemarie Poleck, DO

Family Medicine · Prescott, MINPI 1699851519

Payments from drug & device makers

$4,017in general payments, 2019–2025

Across 288 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$531
  • Novo Nordisk$399
  • Sunovion Pharmaceuticals Inc.$358
  • GSK$342
  • Amgen$284
  • Pfizer$282
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,80695%
  • Education$2105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,017 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$88
Medicare patients
14
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$29,578
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$28,076
TrulicityDulaglutide18$25,791
JardianceEmpagliflozin15$15,361
EliquisApixaban16$13,535
FarxigaDapagliflozin Propanediol16$10,267
Varenicline Tartrate15$3,326
ShingrixVaricella-Zoster Ge/As01b/Pf13$2,896
Albuterol Sulfate HfaAlbuterol Sulfate79$2,831
Diclofenac Sodium32$1,673
Gabapentin122$1,537
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,255
Atorvastatin Calcium77$932
Ventolin HfaAlbuterol Sulfate16$927
Rosuvastatin Calcium67$909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$342$30,97240 claims
Novo NordiskOzempic$399$29,57824 claims
Lilly USA, LLCTrulicity$141$25,79118 claims
Boehringer IngelheimJardiance$79$15,36115 claims
PfizerEliquis$282$13,53516 claims
AstraZenecaFarxiga$261$10,26716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Prescott

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →